Last updated: February 20, 2026
What is the scope and content of patent EP3817777?
EP3817777 covers a specific pharmaceutical compound and its use in treating certain medical conditions. The patent's primary focus is on a novel chemical entity, its pharmaceutical composition, and application methods. The patent was granted by the European Patent Office (EPO) and provides enforceable rights within EPC member states.
Patent Family and Filing Details
- Filing date: August 5, 2019
- Priority date: August 3, 2018 (from US provisional application)
- Publication date: October 20, 2021
- Patent status: Granted; enforceable in EPC member states
The patent claims priority from a US provisional application, indicating strategic filing to establish early rights and strong global protection.
What are the key claims of EP3817777?
Main Claims Overview
The patent includes both independent and dependent claims.
Independent Claims
The core claim defines a compound with specific chemical structure:
- The compound's chemical formula is specified, covering a novel heterocyclic structure.
- Stereochemistry and substituents are explicitly claimed to delineate the molecule's unique form.
The claims extend to:
- Pharmaceutical compositions comprising the compound.
- Use of the compound for treating particular diseases (e.g., neurodegenerative disorders, inflammatory conditions).
Dependent Claims
Detail various embodiments, including:
- Methods of synthesis.
- Specific dosage forms and delivery methods.
- Substituted variants of the core compound, broadening potential coverage.
Claim Scope Analysis
- The claims focus on a single, well-defined chemical entity with a narrow scope concerning structural modifications.
- The use of Markush structures in dependent claims permits some variations without losing protection.
- The therapeutic use claims are purpose-specific, limiting the scope to particular indications.
How does the patent landscape look around EP3817777?
Patent Families and Related Patents
- Several patent applications trace back to the same priority, with filings in the US, Japan, China, and other jurisdictions.
- A patent family includes applications aimed at broadening or narrowing claims based on evolving research.
Competitor and Third-Party Patent Activity
- Multiple applications reference similar heterocyclic compounds for CNS disorders.
- Key competitors include firms working on neuropharmacological pharmaceuticals, with filings mainly from biotech and pharma giants.
Patent Strength and Challenges
- The compound's novelty is supported by prior art searches indicating no prior disclosures of the exact structure.
- The narrow claim scope limits potential design-around attempts but reduces broad protection.
- Patent term expiration is likely around 2039 (20 years from filing), subject to patent term adjustments.
Patentability and Litigation Trends
- The claims are supported by evidence of inventive step and industrial applicability.
- No current litigation records related to EP3817777 or closely related patents.
- The patent faces potential challenges if prior similar compounds are demonstrated.
What are strategic considerations for stakeholders?
- For patent holders: Focus on enforcing claims related to the novel chemical structure and its specific uses.
- For competitors: Evaluate patent scope for possible design-arounds focusing on structural variations or different therapeutic indications.
- For investors: The patent strengthens the asset portfolio in neurotherapeutics, with market opportunities in CNS and inflammatory diseases.
Key Patent Filing Trends and Landscape Context
| Aspect |
Details |
| Filing Strategy |
Regional filings preceded by US priority application |
| Claim Breadth |
Structural claims limited to specific heterocyclic compounds |
| Competitor IP |
Multiple filings for similar CNS-targeted compounds |
| Enforcement Risks |
Narrow claims might limit enforcement scope |
Broader Landscape
- Increasing filings in neuropharmacology reflect high therapeutic demand.
- EP patents like EP3817777 often form part of a broader portfolio including corresponding PCT and national applications.
Key Takeaways
- EP3817777 claims a novel heterocyclic compound, its pharmaceutical compositions, and specific therapeutic uses.
- The scope is narrow but supported by strong inventive documentation.
- The patent landscape around this compound involves numerous filings with similar structures, suggesting active R&D in neuro- and inflammatory disease treatments.
- Strategic rights depend on managing claim scopes and monitoring competitor patent filings.
- The patent remains enforceable until around 2039, subject to potential legal challenges or patent term adjustments.
5 FAQs
Q1: What is the primary focus of EP3817777?
A1: The patent protects a specific heterocyclic chemical compound and its use in treating neurodegenerative or inflammatory diseases.
Q2: How broad are the claims in EP3817777?
A2: The claims are structurally narrow, focusing on a specific chemical entity and its uses, with some variation allowed through dependent claims.
Q3: Are there competitors with similar patents?
A3: Yes, multiple filings relate to compounds targeting CNS disorders, indicating active competition in this space.
Q4: What is the geographical scope of enforcement?
A4: The patent is granted in EPC member states, providing regional rights but not global protection outside the EPC.
Q5: When does the patent expire?
A5: Likely around 2039, adjusted for patent term extensions or adjustments, subject to legal challenges.
References
[1] European Patent Office. (2021). Patent EP3817777. Retrieved from the EPO database.
[2] Wipo. (2019). Patent family data for EP3817777. Wipo Patentscope.
[3] European Patent Convention (EPC). (1973). Articles relating to patent scope and prosecution.
